2020-09-08 23.57.33.jpg
scma_sucrose_dil_grid1_4.tiff
COVID-19

Many regard the coronavirus pandemic as the worst global crisis since WWII. 

Manufacturing billions of coronavirus vaccines in a short time will be the top priority worldwide.

 

ContiVir's technologies have the potential to help with this monumental challenge.

ContiVir's platform for COVID-19 vaccine candidates

Our technology platform has been successfully used for the production of an in-house developed COVID-19 vaccine candidate, demonstrating its potential for tackling the current need for fast, efficient and fully scalable vaccine manufacturing technologies.

Most of the available literature on the production of COVID-19 virus based vaccines reports production in adherent cells with serum-containing media. This approach severely limits its scale-up potential, which is of particular concern considering the billions of vaccine doses required.

Our in-house developed COVID-19 vaccine candidate is based on a non-infectious virus-like-particle (VLP) that resembles the morphology and structure of the SARS-CoV-2 particles but does not contain any of its infective genetic material, thus rendering it extremely safe to produce and handle. These VLPs can be produced in any Biosafety level 1 facility.

Our technologies allowed us to manufacture these VLPs using mammalian suspension cells in chemically-defined cell culture medium, a critical aspect that renders our production process fully scalable for industrial manufacturing. Afterwards, we purified the VLPs with our innovative membrane-based SXC technology, which uses a universal recipe for virus particles and enables much faster processes.

Electron microscopy picture of our purified VLPs obtained with our SXC technology.

Production of COVID-19 vaccines

The World Health Organization (WHO) periodically updates a Draft landscape of COVID-19 candidate vaccines.

ContiVir's Technologies can be used to efficiently manufacture virus, virus vector-based, and VLP-based coronavirus vaccine candidates. Encapsulated nucleic acids can also be purified with our SXC technology.

Candidates in blue can be produced and purified with our platform

Thus, our manufacturing platform offers a fully scalable solution for a wide range of vaccine candidates currently under development.

We are offering lab-scale devices (a single-use tubular reactor kit and a single-use purification kit) to selected coronavirus researchers who are working with one of the above-mentioned approaches and that require research-grade and pre-clinical material to evaluate the effectiveness of their vaccine candidates. 

Contact us for more information.